title: Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus Strains.
abstract: We compared the efficacy of telavancin (TLV) and daptomycin (DAP) in an experimental rabbit endocarditis model caused by two clinically derived daptomycin-resistant (DAPr) methicillin-resistant Staphylococcus aureus (MRSA) strains. TLV treatment significantly reduced MRSA densities in all target tissues and increased the percentage of these organs rendered culture negative compared to those with the untreated control or DAP-treated animals. These results demonstrate that TLV has potent in vivo efficacy against DAPrMRSA isolates in this invasive endovascular infection model.
authors.affiliation: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
authors.forename: Wessam
authors.initials: W
authors.lastname: Abdelhady
authors.affiliation: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.|Division of Infectious Diseases, LAC Harbor-UCLA Medical Center, Torrance, California, USA.|David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors.forename: Arnold S
authors.initials: AS
authors.lastname: Bayer
authors.affiliation: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
authors.forename: Rachelle
authors.initials: R
authors.lastname: Gonzales
authors.affiliation: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
authors.forename: Liang
authors.initials: L
authors.lastname: Li
authors.affiliation: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA yxiong@ucla.edu.|Division of Infectious Diseases, LAC Harbor-UCLA Medical Center, Torrance, California, USA.|David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors.forename: Yan Q
authors.initials: YQ
authors.lastname: Xiong
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D017576:Daptomycin / Q000494:pharmacology* / Q000627:therapeutic use; D004697:Endocarditis, Bacterial / Q000188:drug therapy*; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000472:pathogenicity; D008826:Microbial Sensitivity Tests; D011817:Rabbits
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; D017576:Daptomycin; C487637:telavancin
keywords: DAPr MRSA; MRSA; TLV; daptomycin resistance; endocarditis; infective endocarditis; telavancin